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Introduction
In 1918, the Spanish flu pandemic caused global panic. It
was highly infectious and deadly, causing 50 million
deaths worldwide. The pandemic was caused by the H1N1
influenza virus [11]. Since then, numerous large and small
scale influenza virus epidemics and pandemics have
occurred, placing heavy disease burdens on the public,
and, in 2009, the H1N1 swine-flu pandemic again received
global attention [3, 5]. It is certain that new and
unpredictable influenza virus pandemics are going to take
place in the future, and the disease burden caused by such
a pandemic would be even greater without a fast and an
effective prevention strategy.
Vaccines are the most effective means of preventing
influenza virus infection. Currently, various influenza
virus vaccines have been developed and tested clinically.
Most of the commercially available vaccines are produced
from embryonated chicken eggs. However, production of
egg-based vaccines takes several months and largely
depends on the timely production of the eggs [17]. During
pandemics, the egg-based system is limited in producing a
Received: October 15, 2014
Revised: November 13, 2014
Accepted: November 13, 2014
First published online
November 14, 2014
*Corresponding authors
J.M.L.
Phone: +82-2-2228-1822;
Fax: +82-2-392-7088;
E-mail: jaemyun@yuhs.ac
M.S.
Phone: +82-2-881-1404;
Fax: +82-2-872-2803;
E-mail: mksong@ivi.int
†These authors contributed 
equally to this work.
upplementary data for this 
paper are available on-line only at 
http://jmb.or.kr.
pISSN 1017-7825, eISSN 1738-8872
Copyright© 2015 by
The Korean Society for Microbiology 
and Biotechnology
Current influenza vaccines are produced in embryonated chicken eggs. However, egg-based
vaccines have various problems. To address these problems, recombinant protein vaccines
have been developed as new vaccine candidates. Unfortunately, recombinant proteins
frequently encounter aggregation and low stability during their biogenesis. It has been
previously demonstrated that recombinantly expressed proteins can be greatly stabilized with
high solubility by fusing stabilizing peptide (SP) derived from the C-terminal acidic tail of
human synuclein (ATS). To investigate whether SP fusion proteins can induce protective
immunity in mice, we produced influenza HA and SP fusion protein using a baculovirus
expression system. In in vitro tests, SP-fused recombinant HA1 (SP-rHA1) was shown to be
more stable than recombinant HA1 (rHA1). Mice were immunized intramuscularly with
baculovirus-expressed rHA1 protein or SP-rHA1 protein (2 µg/mouse) formulated with
aluminum hydroxide. Antibody responses were determined by ELISA and hemagglutination
inhibition assay. We observed that SP-rHA1 immunization elicited HA-specific antibody
responses that were comparable to rHA1 immunization. These results indicate that fusion of
SP to rHA1 does not negatively affect the immunogenicity of the vaccine candidate. Therefore,
it is possible to apply SP fusion technology to develop stable recombinant protein vaccines
with high solubility.
Keywords: Pandemic, influenza, hemagglutinin, stabilizing peptide 
S
S
281 Yang et al.
J. Microbiol. Biotechnol.
large amount of vaccines in a short period of time. Recently,
cell-culture-based production of influenza vaccines, which
can overcome the limitations of the egg-based system, has
been clinically approved. In particular, a protein expression
system using recombinant baculovirus-infected insect cells
can produce a large amount of subunit vaccine in a short
period of time [1]. Accordingly, a baculovirus expression
system has been explored and adopted for the production
of various subunit vaccines for different pathogens [19-21].
Adjuvants are commonly used to increase the
immunogenicity of subunit vaccines. Currently, alum is the
most widely used adjuvant and has been employed as a
safe and powerful immune enhancer since 1926 [15].
Various commercially available vaccines for a myriad of
diseases such as DTP, HPV, tetanus, anthrax, Japanese
encephalitis, and hepatitis B are formulated with alum [9].
Despite the use of adjuvants, however, the low solubility
and instability of subunit vaccine during the purification
and storage process are major problems for recombinant
protein vaccines. Furthermore, protein vaccine can be
aggregated by external stresses such as heat, and an
unstable form of protein can induce unpredictable immune
responses that can potentially be harmful to the recipient of
the vaccine [2, 16]. 
Stabilizing peptide (SP) is derived from the C-terminal
acidic tail of synuclein (ATS), and recombinant proteins
fused with SP have been shown to maintain their proper
stable forms under various stresses [6, 10, 12]. According to
previous studies, therapeutic protein fused with SP is
protected from agitation, heat stress, and repeated freeze-
thaw cycles [8, 10, 12, 13]. These studies indicate that SP-
fusion improves the stability, while maintaining the original
characteristics, of the target protein in in vitro conditions.
However, how such increases in stability derived through
SP-fusion would affect the immunogenicity of recombinant
protein vaccines has not been examined.
In this study, we compared the immunogenicity and
protection generated by vaccination of mice with recombinant
influenza HA1 proteins, either with or without SP-fusion,
that were produced via a baculovirus expression system. 
Materials and Methods
Cloning and Protein Expression
Cloning transfer vector. The globular head domain of the
hemagglutinin gene of influenza virus A/New York/3571/2009
(H1N1) strain (rHA1, residues 18-344) was amplified with adaptor
primers that had additional restriction enzyme recognition
sequence for BglII (forward) and XbaI (reverse) at the 5’ end of
each primer. The amplicon was cut with restriction enzymes, and
then inserted into baculovirus transfer vector pAcGP67 (BD
Bioscience, Franklin Lakes, NJ, USA) with a 6× His-tag added at
the C-terminus. The vector for expression of chimeric protein
containing the SP sequence (SP-rHA1) underwent additional
modification to encode acidic tale sequences (Fig. 1A). Construction
of the transfer vectors was conducted in an E. coli system. (Sequence
information for cloned proteins is listed in Supplementary file.)
Production of recombinant virus and protein production in an
insect cell system. The recombinant transfer vectors were
transformed to 7.5 × 105 cells/ml SF9 cells (BD Bioscience) by the
calcium phosphate method and baculovirus was simultaneously
infected to the insect cell. Over two consecutive subcultures, we
obtained high-titer viruses in the supernatants. For recombinant
protein expression, new SF9 cells (2 × 106 cells/ml, 200 ml) were
infected with the supernatants containing recombinant virus and
cultured for 3 days (27°C, 115 rpm), and then the culture media
were collected and concentrated by the ammonium sulfate
Fig. 1. Cloning and expression of recombinant proteins. 
Partial sequences (residues 18-344) of the HA gene from influenza
virus A/New York/3571/2009 (H1N1) strain was cloned into a
baculovirus transfer vector with modifications of histidine tagging
and/or stabilizing peptide fusion (A). Recombinant proteins were
confirmed by SDS-PAGE analysis in reducing condition, and the
status of glycosylation was also confirmed with use of PNGase F (B).
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precipitation method (7 M ammonium sulfate). The precipitate
was re-dissolved in a buffer solution (20 mM Tris-HCl (pH 8.0),
0.5 M NaCl, 5 mM imidazole) and then we purified histidine
tagged proteins using a nickel column (Nickel beads Cat.1018;
ADAR Biotech, USA). The purified protein was eluted from the
column with elution buffer (20 mM Tris-HCl (pH 8.0), 0.5 M NaCl,
255 mM imidazole) and underwent dialysis in 20 mM Tris-HCl
buffer at pH 8.0 containing 10% glycerol. Finally, the dialysate
was concentrated upto 1 mg/ml.
Confirmation of the expressed protein. The protein content in
each concentrate was measured by bicinchoninic acid assay
(Thermo Scientific, USA) and 5 µg of each protein was used for
SDS-PAGE analysis in reducing conditions. Briefly, samples were
mixed with 5× SDS sample buffer, and 2-mercaptoethanol was
added to the final concentration of 0.2%. For verification of proper
glycosylation in the baculovirus protein expression system, aliquots
of samples were pretreated with PNGase F (Sigma Aldrich, St.
Louis, MO, USA) according to the method recommended by the
manufacturer. All samples were heated at 100°C for 5 min and
loaded on 10% Tris-Acetate gel. After separation, protein bands
were visualized by 0.05% Coomassie Brilliant Blue staining.
In Vitro Stability Test Against Freeze/Thaw Stress
Sample preparation. Both recombinant proteins, rHA1 and SP-
rHA1, were diluted in PBS (pH 7.4) to a concentration of 30 µg/ml,
which is the recommended HA concentration in influenza vaccine,
and 500 µl of each solution was placed in a microcentrifuge tube.
Effect of freeze/thaw cycles on recombinant proteins. Samples
were tested by repeated cycles of freezing in liquid nitrogen and
thawing in a 50oC water bath, both for 10 min. Samples that had
completed 20, 40, and 60 cycles were collected and subjected to
SDS-PAGE. The gel was photographed and the density of each
band was semi-quantified using Image J (NIH, USA) software.
Immunogenicity and Protective Efficacy in a Mouse Model
Mice. Six-week-old female Balb/c mice were purchased from
Orient Bio. Mice testing was approved by the Institutional Animal
Care and Use Committee (IACUC) at the International Vaccine
Institute (IVI; no. 2011-009).
Vaccination. Case I. Balb/c mice were immunized three times
every 2 weeks. Mice were vaccinated intramuscularly with
recombinant HA1 protein (rHA1) from H1N1 influenza virus (A/
California/04/09) using a baculovirus expression system or rHA1
protein fused with SP (SP- rHA1) with alum (Thermo Scientific,
USA) as an adjuvant. Either rHA1 or SP-rHA1 was vaccinated
using 2 µg per mouse. Control groups were vaccinated with PBS
by intramuscular route. Mice sera were collected 2 weeks after
every immunization. Case II. Balb/c mice were immunized at
once, in order to confirm the efficacy of minimal vaccination. Mice
were vaccinated in the same manner as Case I (rHA1 group, SP-
rHA1 group, and negative control group). Mice sera were
collected 2 weeks after immunization.
ELISA. Antibody response in vaccinated mice was determined
by ELISA. Briefly, a 96-well plate (NUNC, USA) was coated
overnight at 4oC with 2 µg/ml of rHA1 protein diluted in 50 mM
NaHCO3 buffer (pH 9.6) or A/California/04/09 H1N1 influenza
virus diluted in PBS. Following blocking in 1% BSA (Sigma, USA)
diluted in PBS, the plate was loaded with immunized mice sera
samples. Mice sera were diluted 1:100 in PBS with 1% BSA. Each
of the diluted sera samples was transferred to 5-fold serial dilutions,
and the plate was incubated for 1-2 h at 37oC. After that, all
wells were incubated with 1:3,000 dilutions of goat anti-mouse
horseradish-peroxidase-labeled IgG, IgG1, or IgG2a (Southern
Biotech, USA) in secondary antibodies buffer (PBS with 0.1% BSA
and 0.05% Tween-20) at 37°C for 1-2 h. The development step
was then conducted by using tetramethyl benzidine solution
(Millipore, USA). The reaction was stopped with 1N HCl. The
absorbance values were measured at 450 nm wavelength.
Hemagglutination inhibition assay (HI assay). One day before
performing the assay, mice sera were treated with receptor-
destroying enzyme (RDE) (Denka-Seiken, Japan) overnight at
37oC. The RDE was then inactivated at 56oC for 1 h. PBS was
mixed with the RDE-treated sera, and the sera were diluted 1:10 in
RDE with PBS. The enzyme-treated sera were loaded as 2-fold
serial dilutions into a V-bottom 96-well plate (Greiner Bio-one,
Germany), and 4 hemagglutination units (HAU) of A/California/
04/09 H1N1 influenza virus was added. The plate was incubated
for 1-2 h at room temperature; then, 1% chicken RBC (Fitzgerald,
USA) in Alsever’s solution (Sigma, USA) was added to each well.
Hemagglutination was observed after 1 h at room temperature.
We pooled the samples and the experiments were performed in
duplicates.
Viral challenge. Four weeks after the last immunization, mice
were infected with A/California/04/09 influenza virus (KRIBB,
Korea) at 10 MLD50 dose. The mice were then checked daily for
body weight loss and survival rate for 14 days. The proportion of
body weight change was calculated on the basis of body weight at
0 dpi. After the virus challenge, weight loss ≥20% was used as the
endpoint at which mice were euthanized. Survival rate was
determined by deaths and euthanized mice.
Results
Recombinant Proteins Were Expressed Well in the
Baculovirus Insect Cell System.
Both rHA1 and SP-rHA1 were successfully expressed in
the baculovirus insect cell system. SDS-PAGE in reducing
conditions confirmed the presence of these proteins at the
expected size, and treatment of PNGase F yielded in
smaller bands, indicating proper glycosylation during
expression in the eukaryotic system (Fig. 1B). 
SP-Fusion Enhanced the Stability of rHA1 Protein Over
Repeated Freeze/Thaw Cycle Stress.
After 60 freeze-and-thaw cycles, both recombinant
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proteins showed a gradual loss of stability over repeated
stress (Fig. 2A). However, the densitogram measurements
based on the semi-quantified intensities of each band
demonstrated a relatively slower loss of SP-rHA1 than of
rHA1 (Fig. 2B).
Humoral Immune Response Was Induced by IM Vaccination
with rHA1 Protein.
In previous reports, proteins fused with SP were shown
to be resistant to agitation, freezing/thawing, and heat
stress [10], indicating that the addition of SP grants fusion
protein increased stability and longevity for storage.
Adding to these previous results, we further confirmed the
antiviral activity of the fusion protein (SP-rHA1) compared
with, the non-fusion rHA1 protein.
Mice were immunized three times at two-week interval
via the intramuscular route with 2 µg of rHA1 from H1N1
influenza virus (A/California/04/09) or SP-rHA1 using
alum as an adjuvant. Sera were collected from mice 14 days
after each immunization, in order to examine the antigen-
specific antibody response by ELISA. As shown in Fig. 3,
SP-rHA1 immunization induced levels of antigen-specific
antibody titers that were as high as the levels induced by
rHA1 immunization. Comparing the differences among
antibody isotypes, both rHA1 and SP-rHA1 produced
higher levels of IgG1 than IgG2a. Therefore, rHA1 and SP-
rHA1 immunizations were predicted to induce a Th2-type
immune response.
Neutralizing Antibodies Were Induced by rHA1 Protein
Against Pandemic H1N1 Influenza Virus.
Next, we confirmed neutralizing antibody titers with an
HI assay using mice sera harvested 14 days after the final
vaccinations. As shown in Table 1, SP-rHA1 immunization
induced a higher level of HI titer than rHA1 immunization. In
addition, we further evaluated the serum neutralizing ability
generated by SP-rHA1 immunization via microneutralization
(MN) assay and observed that sera collected 14 days after
the final SP-rHA1 vaccination produced an MN titer of 320
(data not shown). These results suggest that SP-rHA1
immunization induces a effective neutralizing antibody
response.
rHA1 Was Shown to Protect Against Infection of 2009
Pandemic H1N1 Influenza Virus.
Based on these results, vaccinated mice were challenged
with influenza virus to confirm protection against live
virus infection. Four weeks after the final immunization,
the immunized and negative control mice were challenged
intranasally with 10 MLD50 H1N1 influenza virus (A/
California/04/09). Changes of body weight and the
survival rate of the mice were monitored daily, until 2
weeks after the virus challenge. Both the rHA1 and SP-
rHA1 groups showed a 100% survival rate (Fig. 4A) with a
body weight decrease of less than 10% (Fig. 4B). These
Fig. 2. Freeze/thaw stress on recombinant proteins. 
SDS-PAGE analysis of rHA1 and SP-rHA1 showed gradual loss of both proteins over repeated freeze/thaw cycles (A). The intensity of each band
was semi-quantified using Image J software, and the densities are plotted as a function of freeze/thaw cycles (B).
Table 1. HI titer against influenza virus. 
Group HI Titer
PBS N.D.
rHA1 + Alum 480
SP-rHA1 + Alum 800
A/California/04/09 H1N1 influenza virus-specific neutralizing antibody was
examined by HI test.
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results show that immunization of mice with rHA1
generated in a baculovirus expression system effectively
confers protection against influenza virus infection.
Importantly, fusion of SP did not interfere with the ability
of SP-rHA1 to induce a strong antiviral activity, as both SP-
rHA1 immunization and rHA1 immunization produced
comparable levels of protection.
Single Injection of rHA1 Induced a Humoral Immune
Response and Protective Activity Against 2009 Pandemic
H1N1 Influenza Virus.
In addition, we evaluated the level of protection conferred
following a single immunization with rHA1 or SP-rHA1.
Mice were immunized intramuscularly with 2 µg of rHA1
from H1N1 influenza virus (A/California/04/09) or SP-
rHA1 using alum as an adjuvant. Sera were collected
14 days after the immunization to determine antigen-
specific antibody titers using ELISA. Both the rHA1 and
SP-rHA1 groups produced high levels of antigen-specific
serum antibodies. Animals in these groups also induced
higher levels of IgG1 than IgG2a (Fig. 5A). We further
performed an HI assay to determine the neutralizing
antibody titers; however, no neutralizing ability was
detected (data not shown). Next, vaccinated mice were
challenged with live influenza virus to examine the level of
protection produced after a single immunization. Immunized
and control mice were given 10 MLD50 of H1N1 influenza
virus (A/California/04/09) intranasally. Body weight loss
and the survival rate of the mice were recorded daily, until
2 weeks after virus infection. Both the rHA1 and SP-rHA1
groups showed survival rates of about 70% (Fig. 5B). Upon
lethal H1N1 influenza virus challenge, mice in the SP-rHA1
and rHA1 groups lost approximately 20% of their body
weight (Fig. 5C). In these results, imperfect protection
Fig. 3. Influenza antigen-specific antibody responses. 
Balb/c mice were immunized with 2 µg of rHA1 protein from A/California/04/09 influenza virus or SP-rHA1 protein with or without an
adjuvant. For confirming a systemic immune response, mice were immunized intramuscularly with antigen with alum as an adjuvant (A, B). Two
weeks after every immunization, mice sera were collected and their antibodies were examined by ELISA. IgG, IgG1, and IgG2a antibodies were
measured in rHA1 protein-coated (A) and virus-coated conditions (B).
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activity was shown when mice were vaccinated with a
single injection.
Discussion
After the H1N1 Spanish influenza pandemic of 1918,
scientists put in great efforts in order to continuously study
this field, aiming to providing preventive measures against
future influenza virus. Meanwhile, recombinant protein
vaccines have gained immense support as a promising tool
that can generate strong immune responses and confer
protection against viral infections. Accordingly, there has
been an increase in the studies evaluating various
recombinant protein vaccines in order to prevent future
pandemics of viral diseases, and protein vaccines produced
from a baculovirus expression system have been studied
extensively.
However, recombinant protein vaccines possess difficulties
with storage owing to physical disturbances caused by
external factors such as heat, freezing, agitation, and
shearing [9, 22]. Therefore, these protein vaccines require
special measures, such as cold-chain logistics, for transportation
and storage [9, 18]. Such constraints render the use of
protein vaccines in developing countries as very difficult.
To overcome these obstacles, we utilized SP, found in the
acidic tail of human synuclein peptide, as a means of
producing more stable and soluble forms of therapeutic
proteins in vitro. The synuclein family consists of heat-
resistant proteins that do not aggregate under heat stress
[4, 6, 13], and studies have shown that the acidic tails of the
synuclein family are responsible for inducing tolerance
against heat, pH, or other environmental stresses [7, 13, 14].
Furthermore, SP functions to increase the stability and
solubility of recombinant proteins [6, 8, 10].
In the present study, we confirmed the increase in overall
stability of rHA1 as the result of recombinant fusion of SP
as SP-rHA1 was shown to be more stable than rHA1 upon
experiencing repetitive freeze/thaw cycles. Moreover, to
investigate whether the recombinant SP-fusion, which
enhances the stability of the fusion protein in vitro, affects
immunogenicity and protective immunity upon vaccination,
mice were immunized intramuscularly with rHA1 or SP-
rHA1. We observed that SP-rHA1 elicited HA-specific
antibody and a neutralization antibody response that was
comparable to that of rHA1, and mice immunized with SP-
rHA1 vaccine were completely protected against live
influenza virus infection, indicating that SP-fusion does not
negatively affect the immunogenicity of fusion proteins.
Although we do not possess direct data, we speculate that
the presence of SP does not greatly alter the antigen
process and presentation of rHA1, given that comparable
HA1-specific immunity was generated in mice immunized
Fig. 4. Viral resistance against influenza virus challenge. 
At 4 weeks after the last immunizations, mice were infected intranasally with A/California/04/09 H1N1 influenza virus at 10 MLD50. Their
survival rate (A) and body weight loss (B) were checked every day for 14 days.
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with SP-rHA1 and in mice immunized with rHA1.
Taken together, we believe that SP-fusion technology
could be adopted to generate stable recombinant protein
vaccines with high solubility to overcome the current
limitations of protein vaccine storage.
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